3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
CNS
1
Conditions
Pheochromocytoma
1
Paraganglioma
1
Neuroendocrine Tumors
1
Interventions
lutetium Lu 177 dotatate
5
gallium Ga 68 dotatate
3
3-Iodobenzylguanidine
3
Magnetic Resonance Spectroscopy
2
177Lu-octreotide, DOTA(0)-Tyr(3)-
2
vandetanib
1
olaparib
1
fludarabine phosphate
1
copper dotatate CU-64
1
cabozantinib
1
atezolizumab
1
Specimen Handling
1
Lutetium-177
1
Lutetium
1
Iodine-131
1
Interleukin-13
1
Fluorodeoxyglucose F18
1
Everolimus
1
Erlotinib Hydrochloride
1
Cyclophosphamide
1
Biopsy
1
90Y-octreotate, DOTA(0)-Tyr(3)-Thr(8)-
1
3-fluorobenzylguanidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Paraganglioma
×
vandetanib
×
NET
×
Clear all
NCT01941849
2015-12-21
VIBRaNT
University College, London
Phase 1
Withdrawn